Vascular growth factors and angiogenesis in cardiac surgery
Vascular growth factors and angiogenesis in cardiac surgery
复制标题
DOI：
10.1016/s0003-4975(02)04693-3
复制
发表时间：
2003-02-01
影响因子：
4.6
通讯作者：
Ruel, M
中科院分区：
文献类型：
--
作者：
Sellke, FW;Ruel, M
以生长因子蛋白给药或基因治疗的形式的治疗性血管生成已经成为治疗患有严重的不可手术的冠状动脉疾病的患者的新方法。在慢性心肌缺血的动物模型中，已经证明了血管生成生长因子给药后心肌灌注和功能的改善。最近，使用生长因子蛋白或编码这些血管生成因子的基因的初步临床试验已经证明了相关血管生成的临床和其他客观证据。最近的一项研究报告了使用成纤维细胞生长因子（FGF）-2蛋白的治疗性血管生成在无心绞痛和单光子发射计算机断层扫描成像灌注方面的长期有益作用。因此，治疗性血管生成有可能将治疗选择扩展到不是常规心肌血运重建方法的最佳候选人的患者。然而，在血管生成成为治疗严重冠心病患者的标准疗法之前，需要克服内源性抗血管生成影响、严重内皮功能障碍患者内在缺乏反应以及其他限制。(C)2003年由胸外科医师协会发布。
Therapeutic angiogenesis, in the form of growth factor protein administration or gene therapy, has emerged as a new method of treatment for patients with severe, inoperable coronary artery disease. Improved myocardial perfusion and function after administration of angiogenic growth factors has been demonstrated in animal models of chronic myocardial ischemia. Recently, preliminary clinical trials using growth factor proteins or genes encoding these angiogenic factors have demonstrated clinical and other objective evidence of relevant angiogenesis. A recent study reported beneficial long-term effects of therapeutic angiogenesis using fibroblast growth factor (FGF)-2 protein in terms of freedom from angina and perfusion on single-photon emission computed tomographic imaging. Thus, therapeutic angiogenesis has the potential to extend treatment options to patients who are not optimal candidates for conventional methods of myocardial revascularization. However, endogenous antiangiogenic influences, intrinsic lack of response of patients with severe endothelial dysfunction, and other limitations will need to be overcome before angiogenesis becomes a standard therapy for the treatment of patients with severe coronary disease. (C) 2003 by The Society of Thoracic Surgeons.